Eisai Begins Rolling BLA Submission of Lecanemab for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.
Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.
The investigational adeno-associated virus mediated gene therapy is being developed to deliver the protective APOE2 gene to the CNS.
Adverse financial events seen years before diagnosis and become more prevalent after diagnosis
Is there a causal relationship between depressive disorders and late-life neurodegenerative diseases? Or, is their co-occurrence due to confounding or common risk factors, such as aging?
The Lancet Commission added 3 new risk factors for dementia that coupled with the previous 9 lifestyle risk factors might prevent or delay up to 40% of dementias worldwide.
Individuals with severe periodontal disease or edentulism have an increased risk for incident dementia.
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.